These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

252 related items for PubMed ID: 26392415

  • 1.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 2. Concurrent erlotinib and radiotherapy for chemoradiotherapy-intolerant esophageal squamous cell carcinoma patients: results of a pilot study.
    Zhai Y, Hui Z, Wang J, Zou S, Liang J, Wang X, Lv J, Chen B, Zhu H, Wang L.
    Dis Esophagus; 2013 Jul; 26(5):503-9. PubMed ID: 22862289
    [Abstract] [Full Text] [Related]

  • 3. Phase II clinical and exploratory biomarker study of dacomitinib in recurrent and/or metastatic esophageal squamous cell carcinoma.
    Kim HS, Kim SM, Kim H, Pyo KH, Sun JM, Ahn MJ, Park K, Keam B, Kwon NJ, Yun HJ, Kim HG, Chung IJ, Lee JS, Lee KH, Kim DJ, Lee CG, Hur J, Chung H, Park JC, Shin SK, Lee SK, Kim HR, Moon YW, Lee YC, Kim JH, Paik S, Cho BC.
    Oncotarget; 2015 Dec 29; 6(42):44971-84. PubMed ID: 26462025
    [Abstract] [Full Text] [Related]

  • 4. Detection of epidermal growth factor receptor mutation in the peripheral blood of patients with esophageal carcinoma to guide epidermal growth factor receptor-tyrosine kinase inhibitor treatment.
    Xu Y, Xie Z, Lu H.
    J Cancer Res Ther; 2018 Jan 29; 14(1):103-105. PubMed ID: 29516969
    [Abstract] [Full Text] [Related]

  • 5. The salvage therapy in lung adenocarcinoma initially harbored susceptible EGFR mutation and acquired resistance occurred to the first-line gefitinib and second-line cytotoxic chemotherapy.
    Yang CJ, Hung JY, Tsai MJ, Wu KL, Liu TC, Chou SH, Lee JY, Hsu JS, Huang MS, Chong IW.
    BMC Pharmacol Toxicol; 2017 May 10; 18(1):21. PubMed ID: 28486985
    [Abstract] [Full Text] [Related]

  • 6. Effect of the Addition of Cetuximab to Paclitaxel, Cisplatin, and Radiation Therapy for Patients With Esophageal Cancer: The NRG Oncology RTOG 0436 Phase 3 Randomized Clinical Trial.
    Suntharalingam M, Winter K, Ilson D, Dicker AP, Kachnic L, Konski A, Chakravarthy AB, Anker CJ, Thakrar H, Horiba N, Dubey A, Greenberger JS, Raben A, Giguere J, Roof K, Videtic G, Pollock J, Safran H, Crane CH.
    JAMA Oncol; 2017 Nov 01; 3(11):1520-1528. PubMed ID: 28687830
    [Abstract] [Full Text] [Related]

  • 7. Afatinib versus erlotinib as second-line treatment of patients with advanced squamous cell carcinoma of the lung (LUX-Lung 8): an open-label randomised controlled phase 3 trial.
    Soria JC, Felip E, Cobo M, Lu S, Syrigos K, Lee KH, Göker E, Georgoulias V, Li W, Isla D, Guclu SZ, Morabito A, Min YJ, Ardizzoni A, Gadgeel SM, Wang B, Chand VK, Goss GD, LUX-Lung 8 Investigators.
    Lancet Oncol; 2015 Aug 01; 16(8):897-907. PubMed ID: 26156651
    [Abstract] [Full Text] [Related]

  • 8. EGFR mutations in patients with non small-cell lung cancer in Bulgaria and treatment with gefitinib.
    Damyanov D, Koynov K, Naseva E, Bichev S.
    J BUON; 2015 Aug 01; 20(1):136-41. PubMed ID: 25778308
    [Abstract] [Full Text] [Related]

  • 9. Afatinib versus placebo as adjuvant therapy after chemoradiation in a double-blind, phase III study (LUX-Head & Neck 2) in patients with primary unresected, clinically intermediate-to-high-risk head and neck cancer: study protocol for a randomized controlled trial.
    Burtness B, Bourhis JP, Vermorken JB, Harrington KJ, Cohen EE.
    Trials; 2014 Nov 29; 15():469. PubMed ID: 25432788
    [Abstract] [Full Text] [Related]

  • 10. Adding Erlotinib to Chemoradiation Improves Overall Survival but Not Progression-Free Survival in Stage III Non-Small Cell Lung Cancer.
    Komaki R, Allen PK, Wei X, Blumenschein GR, Tang X, Lee JJ, Welsh JW, Wistuba II, Liu DD, Hong WK.
    Int J Radiat Oncol Biol Phys; 2015 Jun 01; 92(2):317-24. PubMed ID: 25968826
    [Abstract] [Full Text] [Related]

  • 11. EGFR mutation L747P led to gefitinib resistance and accelerated liver metastases in a Chinese patient with lung adenocarcinoma.
    Yu G, Xie X, Sun D, Geng J, Fu F, Zhang L, Wang H.
    Int J Clin Exp Pathol; 2015 Jun 01; 8(7):8603-6. PubMed ID: 26339441
    [Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 13.